Researchers at the University of California San Diego School of Medicine have published the first study defining early-onset cirrhosis caused by metabolic dysfunction-associated steatotic liver disease, or MASLD. Published in the September 16, 2026, online edition of Clinical Gastroenterology and Hepatology, the findings reveal that approximately 25% of cirrhosis cases occur before the age of 50, driven by a distinct combination of genetic factors and metabolic conditions.
Understanding Early-Onset MASLD Cirrhosis Risks
According to the study, younger adults who develop cirrhosis from fatty liver disease are not simply experiencing the condition earlier in life. Dr. Rohit Loomba, senior author of the study, gastroenterologist and hepatologist at UC San Diego Health, and chief of the Division of Gastroenterology and Hepatology at the UC San Diego School of Medicine, stated that these patients possess a unique combination of genetic susceptibility and metabolic risk factors that accelerate progression to advanced liver disease.
Investigators analyzed data from approximately 2,400 adults with biopsy-confirmed MASLD who were enrolled in the national NASH Clinical Research Network. The results showed that about one-quarter of the cohort developed cirrhosis before turning 50. Researchers identified type 2 diabetes as a primary driver within this young-onset group.
Limitations in Current Screening Tools
The study highlights significant gaps in standard diagnostic approaches. Dr. Veeral Ajmera, first author of the study, hepatologist at UC San Diego Health, and associate professor of medicine at the UC San Diego School of Medicine, explained that because many commonly used liver fibrosis assessment tools incorporate age as a variable, their sensitivity in younger patients is reduced.
“As current screening tools incorporate age, they miss almost a third of patients with early-onset MASLD cirrhosis,” Ajmera said. Nearly one-third of participants with early-onset cirrhosis in the study received scores that would not normally trigger further clinical evaluation under standard screening thresholds.
Clinical Implications and Cancer Surveillance
Because liver disease is frequently silent until serious complications arise, experts emphasize the need for proactive evaluations. According to Dr. Loomba, younger adults with type 2 diabetes, obesity, or an elevated genetic risk may benefit from more proactive liver assessments to catch scarring before it reaches end-stage failure.
Furthermore, cirrhosis serves as a major risk factor for hepatocellular carcinoma, the most common form of liver cancer. Identifying high-risk individuals at an earlier stage creates crucial opportunities for appropriate cancer surveillance and medical intervention before malignancy develops. UC San Diego Health operates a multidisciplinary MASLD program that brings together hepatologists, endocrinologists, obesity medicine specialists, dietitians, and clinical trials to evaluate emerging therapies for advanced fibrosis and related conditions.
Worth a look